See more : CloudCoCo Group plc (CLCO.L) Income Statement Analysis – Financial Results
Complete financial analysis of 89bio, Inc. (ETNB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 89bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chubb Limited (CB) Income Statement Analysis – Financial Results
- OSE Immunotherapeutics SA (OSE.PA) Income Statement Analysis – Financial Results
- Studio Retail Group plc (STU.L) Income Statement Analysis – Financial Results
- Babcock International Group PLC (BCKIF) Income Statement Analysis – Financial Results
- Omai Gold Mines Corp. (OMGGF) Income Statement Analysis – Financial Results
89bio, Inc. (ETNB)
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| Gross Profit | -273.00K | -240.00K | -79.00K | -60.00K | -17.00K | -6.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 122.23M | 80.80M | 70.33M | 36.20M | 21.35M | 13.68M |
| General & Administrative | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.97M | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Other Expenses | 0.00 | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Operating Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Cost & Expenses | 151.20M | 102.25M | 89.74M | 49.36M | 26.64M | 15.16M |
| Interest Income | 0.00 | 2.16M | 148.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.59M | 1.92M | 674.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 273.00K | 240.00K | 79.00K | 60.00K | 17.00K | 6.00K |
| EBITDA | -134.46M | -99.85M | -90.19M | -49.50M | -57.19M | -16.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -151.20M | 102.25M | -89.74M | -49.36M | -26.64M | -15.16M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 12.88M | 242.00K | -526.00K | -203.00K | -30.56M | -986.00K |
| Income Before Tax | -138.32M | -102.01M | -90.27M | -49.56M | -57.20M | -16.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.87M | 19.00K | -147.00K | -59.00K | 218.00K | 28.00K |
| Net Income | -142.19M | -102.03M | -90.12M | -49.50M | -57.42M | -16.18M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| EPS Diluted | -2.00 | -2.93 | -4.48 | -3.08 | -5.40 | -3.53 |
| Weighted Avg Shares Out | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
| Weighted Avg Shares Out (Dil) | 71.17M | 34.81M | 20.10M | 16.09M | 10.64M | 4.58M |
A Perfect Storm In Pharmacotherapy: The Opportunity To Invest In NASH
NASH, or nonalcoholic steatohepatitis, is a liver inflammatory disease that can progress to fibrosis and cirrhosis. NASH is now the second leading cause of liver transplantation, and the US patient population is forecast to increase from 16 million in 2015...
89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering
89bio announced the pricing of its previously announced underwritten public offering of 16,923,077 shares of its common stock at a public offering price per share of $16.25 The post 89bio Announces Upsized Pricing Of $275 Million Common Stock Public Offering...
Why Shares of 89bio Soared This Week
89bio's lead therapy pegozafermin is seen as a treatment for NASH and hypertriglyceridemia. No NASH drug has been approved yet by the FDA.
89bio's public stock offering upsized by 38%, priced at a 4% discount
89bio Inc. ETNB, +23.83% said Friday that its public offering of stock, which the biopharmaceutical company launched after a 55% surge in its stock in the past two days, was upsized by about 38%. The company said it sold 16.92...
89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study
Data from a phase IIb study showed that treatment with 89bio's (ETNB) lead candidate improved fibrosis improved fibrosis at 3.5 times the rate of the placebo without worsening NASH.
Biotech Stock Surges on Mid-Stage Drug Trial Success
The shares of 89bio Inc ( NASDAQ:ETNB) are up 38.2% to trade at $15.11 at last check, after the biotech name revealed its experimental drug pegozafermin to treat nonalcoholic steatohepatitis (NASH) -- a type of fatty liver disease --...
Why Is 89bio (ETNB) Stock Up 34% Today?
89bio (NASDAQ: ETNB ) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial. The goal of this study is to determine the effectiveness of pegozafermin in treating patients with NASH.
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
Small biotech company 89bio scored a win Wednesday in fatty liver disease, and ETNB stock rocketed well above its 50-day moving average. The post 89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease appeared...
89bio's stock rallies 48% on new NASH data
Shares of 89bio Inc. ETNB, -7.06% soared about 48% in premarket trading on Wednesday after the company said its experimental treatment for nonalcoholic steatohepatitis (NASH) led to NASH resolution compared to placebo in a Phase 2b clinical trial. The drug,...
89Bio: A Promising NASH Innovator
As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer an intriguing solution for NASH. Early pegozafermin data showed extremely strong liver fat reduction as well as improvement in NASH.
Source: https://incomestatements.info
Category: Stock Reports